15 billion, adding a promising treatment for digestive disorders to its portfolio.

.

Eastern Time on Monday, May 22, 2023 to discuss the Transaction. (RTTNews) - GI-focused healthcare company Ironwood Pharmaceuticals, Inc.

22, 2023, 07:18 AM.

80.

. 4 million of income tax expense for the. .

S.

Ironwood Pharmaceuticals plans to buy a Swiss biotech for $1 billion as the Boston drug firm seeks to strengthen its focus on treatments for gastrointestinal diseases. Credit: National Cancer Institute on Unsplash. .

class=" fc-smoke">May 22, 2023 · Ironwood Pharmaceuticals, Inc. .

class=" fc-smoke">May 22, 2023 · Ironwood Pharmaceuticals, Inc.

.

. 9 million of income tax benefit in the second quarter of 2021, primarily related to the release of its valuation allowance against the majority of its deferred tax assets.

. Ironwood Pharmaceuticals, Inc.

4 million of income tax expense for the full year of 2022, the majority of which was non-cash, as Ironwood continues to utilize net operating losses to offset taxable income for federal purposes and in many states.

22% adding to the increasing line. . m.

m. The forecasts range from a low of 9. . Glassdoor gives you an inside look at what it's like to work at Ironwood Pharmaceuticals, including salaries, reviews, office photos, and more. S.

.

. Ironwood Pharmaceuticals plans to buy a Swiss biotech for $1 billion as the Boston drug firm seeks to strengthen its focus on treatments for gastrointestinal diseases.

.

4 million of income tax expense in the fourth quarter of 2022 and $77.

class=" fc-smoke">May 22, 2023 · Ironwood Pharmaceuticals, Inc.

S.

Ironwood, which makes the.